{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-270798","form_type":"8-K","ticker":"SNSE","cik":"0001829802","company_name":"Sensei Biotherapeutics, Inc.","filed_at":"2023-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.828544+00:00","generated_at":"2026-06-08T21:26:23.049015+00:00","sec_items":["7.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Sensei Biotherapeutics board unanimously rejects Newtyn's $1.00/share takeover bid","bullets":["Received unsolicited proposal from Newtyn Management to acquire all shares at $1.00/share in cash.","Board unanimously determined proposal substantially undervalues the company and its future prospects.","Company believes it is well-positioned to execute strategy and create long-term value for stockholders.","Rejection formalized on November 6, 2023; no further terms disclosed."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-270798","json":"https://secwatch.observer/filing/0001193125-23-270798.json","markdown":"https://secwatch.observer/filing/0001193125-23-270798.md","text":"https://secwatch.observer/filing/0001193125-23-270798.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1829802/000119312523270798/0001193125-23-270798-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1829802/000119312523270798/d471756d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T21:26:23.049015+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}